Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance

Fig. 1

Disease modifying anti-rheumatic drug (DMARD) escalation patterns. Respondents were asked to select the number (A) and types (B) of conventional DMARDs that a patient should fail prior to starting a biologic. Abbreviations AZA azathioprine, CSA cyclosporine, CYC cyclophosphamide, MMF mycophenolate, MTX methotrexate, TAC  tacrolimus

Back to article page